The hottest thesis in autoimmune disease right now is B-cell depletion. CAR-T therapies are producing jaw-dropping remissions in lupus. Bispecific T-cell engagers are racing into clinical trials for rheumatoid arthritis. Everybody wants to kill B cells.
But here’s the problem nobody’s solved yet: every one of those approaches relies on T cells to do the killing. And T cells come with baggage — cytokine release syndrome, neurotoxicity, the logistical nightmare of manufacturing patient-specific cell products. What if there was a way to get the same deep B-cell depletion without involving T cells at all?
Commit Biologics, a Danish biotech spun out of Aarhus University, thinks the answer has been sitting in immunology textbooks for decades: the complement system.
Their proprietary BiCE™ platform — Bispecific Complement Engagers — uses single-domain antibodies to recruit complement protein C1q directly to target cells. Instead of activating T cells and hoping they don’t overreact, BiCE™ molecules trigger the complement cascade right at the cell surface. The result, at least in non-human primates: deep, sustained B-cell depletion after a single dose, lasting more than four weeks. And the safety profile? No adverse clinical observations. No cytokine release.
I’m sorry, what? Deep B-cell depletion with no cytokine release? In a field where CRS management is basically its own medical subspecialty, that’s the kind of data point that makes you read the press release twice.
The Biotech Voyager
Early-stage biotech signals, personalized.
The signals that matter to you — contextualized and written directly to you — so you cut through the noise and immediately understand why it matters.
The company just closed a €21.5 million seed round led by Novo Holdings, Bioqube Ventures, and Korys, with additional support from an Innovation Fund Denmark grant. When Novo Holdings leads your seed, the Scandinavian biotech ecosystem is telling you something. They’ve also brought in Thomas Andresen as CEO — a serial biotech founder whose hiring signals this isn’t a platform looking for a problem. They’re building to move fast toward clinical candidate nomination later this year.
The BiCE™ platform is modular by design. The same plug-and-play architecture that targets B cells in autoimmune disease can be redirected against tumor-associated antigens in oncology. Preclinical data reportedly shows BiCE™ molecules induce superior complement-mediated cell killing compared to clinically approved T-cell engagers and ADCC-enhanced antibodies. That’s a bold claim, but the NHP data at least suggests the platform can back it up.
Here’s why this matters for the broader landscape: the B-cell depletion race has been a T-cell-centric conversation. Kali Therapeutics just inked a $1.23 billion deal with Sanofi for a trispecific T-cell engager. Prolium Bioscience launched with $50M for a CD20×CD3 bispecific. Imviva is putting up 100% response rates with allogeneic CAR-T in lupus. All T-cell dependent. All carrying cytokine risk.
Commit is asking a fundamentally different question: what if the immune system has a quieter, cleaner weapon that’s been underutilized? The complement cascade predates T-cell biology by a few hundred million years of evolution. Maybe it’s time it got a turn.
